» Articles » PMID: 9563744

Circulating Adhesion Molecules in Cystic Fibrosis

Overview
Specialty Critical Care
Date 1998 May 1
PMID 9563744
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

A marked influx of inflammatory cells occurs into the airways of patients with cystic fibrosis (CF), which may contribute to the development of lung injury. Leukocyte-endothelial adhesion molecules play a crucial role in the recruitment of inflammatory cells, and soluble forms of these molecules have been shown to increase in several inflammatory diseases. By using a capture ELISA, we determined serum levels of soluble ICAM-1 (sICAM-1), E-selectin (sE-selectin), and VCAM-1 (sVCAM-1) in patients with CF, in stable clinical conditions (n = 29, mean age: 25.8+/-1.5 yr), and healthy control subjects (n = 12, mean age: 27.6+/-1.5 yr). Clinical, spirometric, microbiological, and hematological assessments were made in all subjects. sICAM-1 and sE-selectin concentrations, but not sVCAM-1 levels were significantly increased in CF patients as compared with normal subjects (both p < 0.001). sICAM-1 levels were inversely related to FEV1 values (r = -0.519, p = 0.004) and Schwachman score (r = -0.405, p = 0.03) in CF patients. In 7 of 29 CF patients, soluble adhesion molecule levels were determined not only at the time of stable clinical conditions, but also before and after antibiotic treatment for a pulmonary exacerbation. sICAM-1 and sE-selectin levels increased in all patients at the time of the exacerbation, compared with levels at the time of stable conditions (p < 0.02 for both comparisons); antibiotic treatment induced a significant decrease of both circulating adhesion molecules (p < 0.02). The elevated serum levels of sICAM-1 and sE-selectin in CF patients, even when they are clinically stable, may reflect the marked and persistent inflammatory process in the disease.

Citing Articles

A New Frontier in Cystic Fibrosis Pathophysiology: How and When Clock Genes Can Affect the Inflammatory/Immune Response in a Genetic Disease Model.

Carbone A, Vitullo P, Di Gioia S, Castellani S, Conese M Curr Issues Mol Biol. 2024; 46(9):10396-10410.

PMID: 39329970 PMC: 11430433. DOI: 10.3390/cimb46090618.


Pulmonary Vascular Dysfunctions in Cystic Fibrosis.

Amoakon J, Mylavarapu G, Amin R, Naren A Physiology (Bethesda). 2024; 39(4).

PMID: 38501963 PMC: 11368519. DOI: 10.1152/physiol.00024.2023.


Multimodal analysis of granulocytes, monocytes, and platelets in patients with cystic fibrosis before and after Elexacaftor-Tezacaftor-Ivacaftor treatment.

Schmidt H, Hopfer L, Wohlgemuth L, Knapp C, Mohamed A, Stukan L Front Immunol. 2023; 14:1180282.

PMID: 37457734 PMC: 10347380. DOI: 10.3389/fimmu.2023.1180282.


Respiratory Infection and Inflammation in Cystic Fibrosis: A Dynamic Interplay among the Host, Microbes, and Environment for the Ages.

Yu C, Kotsimbos T Int J Mol Sci. 2023; 24(4).

PMID: 36835487 PMC: 9966804. DOI: 10.3390/ijms24044052.


Age-Related Progression of Microvascular Dysfunction in Cystic Fibrosis: New Detection Ways and Clinical Outcomes.

Kreslova M, Sykorova A, Bittenglova R, Schwarz J, Pomahacova R, Jehlicka P Physiol Res. 2021; 70(6):893-903.

PMID: 34717066 PMC: 8815466. DOI: 10.33549/physiolres.934743.